

To

Date: 23.05.2026

The Manager
BSE Limited
P. J. Towers, Dalal Street
Mumbai-400001
(BSE Scrip Code: 544742)

The Manager,
NSE Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai- 400051.
(NSE Symbol: SAIPARENT)

Dear Sir/Madam,

Unit: Sai Parenterals Limited

Sub: Statement on Deviation or Variation of funds under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 32 of The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019 this is to inform the Exchanges that there are no deviation(s) or variation(s) in respect of the utilization of the proceeds of the Initial Public Offer (IPO) of the Company during the quarter and year ended on March 31, 2026. Please find enclosed herewith a statement in this regard.

This is for the information and records of the Exchanges, please.

Thanking you.

**Yours faithfully,
For Sai Parenterals Limited**

**Mr. Anil Kumar Karusala
Managing Director
(DIN- 01866646)**

Encl: as above

Statement of Deviation or Variation in utilization of funds raised

Name of listed entity				Sai Parenterals Limited			
Mode of Fund Raising				Initial Public Offer (IPO)			
Type of Instrument				Equity			
Date of Raising Funds				24 March 2026 to 27 March 2026 (Anchor Issue date: 23 rd March 2026)			
Amount Raised				2,850 millions			
Report filed for Quarter ended				Quarter and year ended as on March 31, 2026.			
Monitoring Agency				Applicable			
Monitoring Agency Name, if applicable				M/s. India Ratings & Research Private Limited			
Is there a Deviation / Variation in use of funds raised				No			
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders				Not applicable			
If Yes, Date of shareholder Approval				Not applicable			
Explanation for the Deviation / Variation				Not applicable			
Comments of the Audit Committee after review				NIL			
Comments of the auditors, if any				NIL			
Sr. No	Original Object	Modified Object, if any	Original Allocation (in Millions)	Modified allocation, if any	Funds Utilised (in Millions)	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1.	Capacity expansion and upgradation of manufacturing facilities	Not Applicable	1107.95	0	0	NA	--
2.	Establishment of a new R&D Centre	Not Applicable	180.23	0	0	NA	--
3.	Repayment / p-repayment- of certain outstanding borrowings	Not Applicable	143.02	0	0	NA	--
4.	Working capital requirements	Not Applicable	330.00	0	0	NA	--
5.	Repayment of bridge loan and term loan availed for investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the acquisition of Noumed Pharmaceuticals Pty Limited (Australia)	Not Applicable	356.41	0	0	NA	--
6.	General Corporate Purposes	Not Applicable	447.40	0	0	NA	--
7.	Issue Related Expenses	Not Applicable	284.99	0	0	NA	--